2013
Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma
Scortegagna M, Ruller C, Feng Y, Lazova R, Kluger H, Li JL, De SK, Rickert R, Pellecchia M, Bosenberg M, Ronai ZA. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma. Oncogene 2013, 33: 4330-4339. PMID: 24037523, PMCID: PMC3955742, DOI: 10.1038/onc.2013.383.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinogenesisCell Line, TumorForkhead Box Protein O3Forkhead Transcription FactorsGene Knockout TechniquesHumansIndazolesLung NeoplasmsLymphatic MetastasisMelanoma, ExperimentalMiceMice, KnockoutMutation, MissenseProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafPTEN PhosphohydrolasePyrimidinesPyruvate Dehydrogenase Acetyl-Transferring KinaseSignal TransductionSkin NeoplasmsTissue Array AnalysisConceptsPhosphoinositide-dependent kinase 1Protein kinase CAGC kinasesSerine/threonine protein kinasePDK1 expressionThreonine protein kinaseImportant cellular processesDirect genetic evidenceGene expression analysisActivity of AktCellular processesProtein kinaseGenetic evidenceExpression analysisPDK1 deletionKinase 1Kinase CElevated phosphorylationGenetic inactivationKinaseMelanoma invasionMelanoma developmentColony formationPharmacological inhibitionInhibits metastasis
2009
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research 2009, 15: 1076-1085. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.ccr-08-2280.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBenzenesulfonatesCarboplatinCell Line, TumorDisease-Free SurvivalDrug Delivery SystemsHumansMelanomaMitogen-Activated Protein Kinase 3NiacinamidePaclitaxelPhenylurea CompoundsPyridinesReceptors, Vascular Endothelial Growth FactorSkin NeoplasmsSorafenibTreatment OutcomeConceptsSerine/threonine-protein kinase 1Mitogen-activated protein kinase pathwayHigher ERK1/2Protein kinase 1Fibroblast growth factor receptor 1Protein kinase pathwayReceptor tyrosine kinasesPlatelet-derived growth factor receptor betaGrowth factor receptor betaVEGF-R2 expressionSorafenib targetsB-RAF V600E mutationGrowth factor receptor 1C-RafKinase pathwayVascular endothelial growth factor receptor 2B-RafKinase 1Kinase 1/2Tyrosine kinaseEndothelial growth factor receptor 2Factor receptor 1ERK1/2Kinase inhibitorsMultitarget kinase inhibitor